GPC1 and cholangiocarcinoma: There have been three preclinical trials of ADCs for CCA using murine models whose targeted antigens were human epidermal growth factor receptor 2 (HER2) [23], mucin 1 (MUC1) [24], and glypican-1 (GPC1) [25] (Table 1).